Drug Database
YP

Ypeginterferon alpha-2b (PegBeron)

✓ Approved

Xiamen Amoytop Biotech Co.ltd · Recombinant Proteins · Recombinant Proteins

What is Ypeginterferon alpha-2b?

Ypeginterferon alpha-2b is a recombinant proteins developed by Xiamen Amoytop Biotech Co.ltd. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesPegBeron
CompanyXiamen Amoytop Biotech Co.ltd
Drug ClassRecombinant Proteins
RouteInjectable (Others), Subcutaneous Injection
StatusApproved

Therapeutic Indications

Ypeginterferon alpha-2b is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Essential thrombocythaemiaPhase II

Related Research Articles

PubMedmedRxiv : the preprint server for health sciences2026-07-17

Standardized, repeatable ulcerative colitis histology scoring and endpoint assessment using an automated, foundation model-based tool.

Tahir Waleed W, Shamshoian John J, Tauber John J, Clinton Lani K LK et al.

In clinical trials for ulcerative colitis (UC), pathologists assess disease severity through standardized histological indices, including the Geboes Score, Robarts Histopathology Index (RHI), and Nancy Histologic Index (NHI). Despite strong associations with clinical outcomes, histologic scoring suffers from inter- and intra-reader variability, and consensus criteria for histologic remission remain uncertain. Through a consortium approach, we developed an artificial intelligence-based measurement (AIM) tool for scoring histology in UC mucosal biopsies (AIM-HI UC). This model, trained on a large dataset of UC biopsies (N=10,230), utilizes additive multiple instance learning models leveraging PLUTO, a pathology foundation model, that predict each of the Geboes subgrades, from which the Geboes grade-level score, RHI, and NHI can be calculated. Evaluation of this model on a standalone verification set including clinical trial specimens established algorithm non-inferiority and/or superiority relative to standard qualified pathologists through comparison of algorithm-consensus and pathologist-consensus agreement metrics (non-inferior if difference >-0.1, superior if difference >0, inclusive of confidence intervals). AIM-HI UC was determined to be non-inferior to pathologists (N=3) for the prediction of all seven Geboes subgrades, grade-level Geboes, RHI, NHI, histologic improvement (GS < 3.1), 2A histologic remission (GS<2A.0), and 2B histologic remission (GS<2B.0). AIM-HI UC was superior to pathologists for several Geboes subgrades (GS 0, GS 1, GS 2B, and GS 5), as well as grade-level Geboes, RHI, and positive percent agreement of 2A histologic remission. The model was shown to be greater than 99% repeatable for all histologic scoring metrics examined. Model-derived scores were shown to strongly correlate with canonical histologic features of inflammation, including the proportion of total epithelium that is inflamed (Spearman r=0.83; p<0.01), the proportion of neutrophils localized within crypt epithelium (Spearman r=0.83, p<0.01), and the amount of mucosal area classified as erosion or ulceration (Spearman r=0.80, p<0.01). Overall, these results suggest that AIM-HI UC has the potential to improve consistency of UC histology interpretation, providing a path toward standardization of UC histology scoring in clinical trials.

PubMedmedRxiv : the preprint server for health sciences2026-07-17

Alterations in Early Alpha-band Connectivity emerge in Infancy among children later diagnosed with Autism.

Chung Haerin H, An Winko W WW, Wilkinson Carol L CL, Davila Mejia Gabriela G et al.

Autism is a heterogeneous neurodevelopmental condition, often accompanied by challenges in language and cognitive development. Although atypical functional connectivity (FC) has been reported in autism, the timing of when it first emerges and its relevance for later behavior remain poorly understood. In this study, we examined developmental trajectories of alpha-band FC and network organization across the first three years of life. We computed global alpha-band measures, including peak alpha connectivity frequency (PACF), mean FC, clustering coefficient, and modularity, to characterize nonlinear developmental trajectories from longitudinal EEGs collected from 238 children (3-36-month-olds) with (Autism; n=58) and without (LL-noAutism; n=180) autism. Network-based statistics (NBS-Predict) identified subnetworks contributing to group differences at each age. Exploratory graph analyses (EGA) examined associations among FC, network measures, and language outcomes. We observed that PACF increased linearly with age in both groups. Global alpha-band connectivity measures showed a similar developmental pattern, with mean global FC, clustering coefficient, and modularity all increasing rapidly during the first year in both groups. Thereafter, these measures declined in the Autism group but continued to gradually increase in the LL-noAutism group. Compared to LL-noAutism, NBS-Predict identified both hyper- and hypo-connectivity subnetworks in Autism at 3 months, followed by a hypo-connectivity subnetwork at 24 and 36 months. EGA indicated that early hyperconnectivity predicted later hypoconnectivity and was associated with subsequent network organization and language outcomes. These findings indicate that altered alpha-band connectivity trajectories are detectable in infancy in children later diagnosed with autism and may contribute to later differences in developmental outcomes.

PubMedConsortium psychiatricum2026-07-17

Effects of Mandala Coloring on Alpha Brain Activity and Anxiety Symptoms among Students at Universiti Sains Malaysia: A Randomized Controlled Trial.

Chang Xin Ni XN, Othman Azizah A, Yusoff Nasir N, Zulkifly Mohd Faizal Mohd MFM

University students commonly experience stress and anxiety, which can negatively affect their academic performance. Mandala coloring has gained attention as a therapeutic art-based activity that may help alleviate symptoms of anxiety. Changes in brain activity, particularly in the alpha power, are known to reflect psychological states and responses to interventions. This study investigated the effects of mandala coloring on alpha brain activity and anxiety symptoms among students at Universiti Sains Malaysia. In a randomized experimental study, sixty students aged 18 to 25 years (M=22.97, SD=1.03) with moderate to high anxiety levels were randomly assigned to either an intervention group (n=30), which colored a geometric mandala for 20 minutes, or a control group (n=30), which colored a blank circle. Brain activity was recorded using electroencephalography (EEG), and anxiety levels were assessed before and after the session using the Malay version of the Beck Anxiety Inventory. Data were analyzed using a mixed-design analysis of variance (ANOVA) with group (intervention vs. control) as the between-subjects factor, and time and brain regions as the within-subjects factor. Both groups showed reductions in anxiety symptoms over time, with no significant differences between groups (F(1; 56)=0.03, p=0.87). However, EEG changes across brain regions differed between groups, with mandala coloring leading to increased frontal alpha power (F(3; 156)=3.21, p=0.03). Mandala coloring was associated with increased frontal alpha power, suggesting enhanced relaxation and focused attention. Anxiety symptoms decreased in both coloring groups, indicating that coloring in general may support emotional regulation and well-being. Taken together, these findings suggest that coloring-based activities may serve as useful therapeutic tools for reducing anxiety and improving focus among university students.

PubMedIndian journal of pediatrics2026-07-17

A Novel MAN2B1 Variant in a Child with a Unique Presentation of Alpha-Mannosidosis.

Mittal Payal P, Bhalla Kapil K, Acharya Rohan R, Hotwani Lipika L

PubMedJournal of food protection2026-07-17

Domestic cutting boards as reservoirs of virulent and antimicrobial-resistant Listeria monocytogenes and Escherichia coli.

de Oliveira Janaina Prieto JP, da Silva Dionice Capistrano DC, Tadielo Leonardo Ereno LE, Rodrigues Dos Santos Emanoelli Aparecida EA et al.

Cutting boards are key food-contact surfaces in domestic kitchens and may act as reservoirs for foodborne pathogens and antimicrobial-resistant bacteria. This study investigated the presence of Listeria monocytogenes and Escherichia coli in wooden and plastic cutting boards collected from Brazilian households, focusing on virulence and biofilm-associated genes, adhesion capacity, and resistance to antibiotics and sanitizers. From 100 cutting boards analyzed, 16 L. monocytogenes isolates and 15 E. coli isolates were recovered. Clinically relevant L. monocytogenes serotypes (1/2a, 1/2b, and 4b) were identified. Both species showed a high prevalence of genes associated with virulence and biofilm formation, although most isolates were classified as weakly adherent in vitro conditions. Antimicrobial susceptibility testing revealed a high frequency of multidrug resistance, particularly in E. coli, with 60.0% of isolates identified as extended-spectrum β-lactamase producers. Several L. monocytogenes isolates also showed resistance to clinically important antimicrobials. All sanitizers tested were effective under experimental conditions. These findings indicate that domestic cutting boards can harbor bacteria combining virulence potential and antimicrobial resistance, highlighting their role in household food safety and the dissemination of antimicrobial resistance.

PubMedThe lancet. Gastroenterology & hepatology2026-07-17

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.

Reinisch Walter W, Stepek David D, Kempinski Radoslaw R, Danese Silvio S et al.

Ulcerative colitis is a chronic inflammatory disease affecting the colon and rectum. We aimed to investigate the efficacy and safety of duvakitug, an anti-TNF-like cytokine 1A (TL1A) monoclonal antibody, in adults with moderately to severely active ulcerative colitis. In this multicentre, placebo-controlled, phase 2b study, we randomly assigned (1:1:1) adults aged 18-75 years with moderately to severely active ulcerative colitis (including patients with inadequate response, loss of response, or intolerance to previous conventional or advanced therapies) to receive a 2250 mg loading dose of duvakitug (subcutaneously), followed by either 450 mg or 900 mg doses every 2 weeks, or placebo loading dose followed by placebo every 2 weeks. The primary endpoint was clinical remission (modified Mayo score) at week 14, analysed using Bayesian methodology. A duvakitug dose was declared successful if the posterior probability that the response rate exceeded placebo was 0·90 or greater. Analyses were done in the modified intention-to-treat population, which included all patients who received at least one dose of their assigned treatment. This trial was registered with ClinicalTrials.gov, NCT05499130, and has been completed. Patients were enrolled between Sept 30, 2022 and Nov 12, 2024. We screened 260 patients with ulcerative colitis. Of these, we randomly assigned 137 (53%) patients to receive duvakitug (n=47 450 mg and n=46 900 mg) or placebo (n=44; modified intention-to-treat analysis set). Patients had a mean age of 41·0 years (SD 13·1); 86 (63%) were men, 51 (37%) were women, and 132 (96%) were White. 43 (31%) patients had previous exposure to an approved advanced therapy. 17 (36%) of 47 patients in the duvakitug 450 mg group and 22 (48%) of 46 patients in the duvakitug 900 mg group were in clinical remission at week 14, compared with nine (20%) of 44 patients in the placebo group. Differences in posterior mean response rates versus placebo were 15% (95% credible interval [CrI] -3 to 33) for duvakitug 450 mg and 26% (95% CrI 8 to 44) for duvakitug 900 mg, with posterior probabilities of superiority to placebo exceeding the prespecified threshold for declaring efficacy (0·95 in the 450 mg group and >0·99 in the 900 mg group). Adverse event incidence was similar with duvakitug (23 [49%] of 47 patients in the 450 mg group and 20 [43%] of 46 in the 900 mg group) and placebo (23 [52%] of 44). The most frequently occurring adverse events were anaemia (one in the 450 mg group, one in the 900 mg group, and three in the placebo group) and upper respiratory tract infection (three in the 450 mg group, one in the 900 mg group, and one in the placebo group). One serious adverse event occurred in the 900 mg group (non-infective oophoritis) and one in the placebo group (intracranial haemorrhage). Duvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis. Teva and Sanofi.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Ypeginterferon alpha-2b